Phase 2 Study to Evaluate the Safety and Efficacy of IZN-6N4 for the Prevention of Chemo-Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2016
At a glance
- Drugs IZN 6N4 (Primary)
- Indications Stomatitis
- Focus Therapeutic Use
- Sponsors Izun Pharma
- 17 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Jan 2017.
- 13 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Jan 2016 According to an Izun Pharmaceuticals media release, the results of this study will be presented at the Biotech Showcase, in January 2016.